SavedAdd your journal

Journals / Retina-Vitreus / 2007 / Cilt: 15 - Sayı: 3

Intravitreal bevacizumab in a patient with neovascular glaucoma due to central retinal vein occlusion

Santral retinal ven tıkanıklığına bağlı neovasküler glokomda intravitreal bevacizumab’ın etkinliği

Figen BATIOĞLU
Neslihan ASTAM
Emin ÖZMERT
Pages
221–223
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Additionally it may be used as an adjunct before glaucoma or vitreoretinal surgery

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Intravitreal bevacizumab was injected in a patient with neovascular glaucoma due to central retinal vein occlusion in order to decrease vascular leakage from iris vessels.
📊
Key Findings & Data:A 46 -year-old man with central retinal vein occlusion in the right eye presented with neovascularization of the iris and intraocular pressure (IOP) of 46 mmHg.
💡
Conclusion & Impact:Additionally it may be used as an adjunct before glaucoma or vitreoretinal surgery
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Glokom · neovasküler · Anjiyografi

Abstract

Intravitreal bevacizumab was injected in a patient with neovascular glaucoma due to central retinal vein occlusion in order to decrease vascular leakage from iris vessels. A 46 -year-old man with central retinal vein occlusion in the right eye presented with neovascularization of the iris and intraocular pressure (IOP) of 46 mmHg. Retinal photocoagulation could not be continued because of corneal edema related to high IOP causing decreased fundus visualization. Morphologic changes and vascular leakage were evaluated before and after intravitreal injection by iris fluorescein angiography. Decrease in leakage was detected as early as 2 day -one week after injection. No inflammation or relapse was seen within the follow-up of 1-4 weeks. Intravitreal bevacizumab injection may be a useful alternative treatment for patients with neovascular glaucoma in whom inadequate visualization precludes treatment with retinal photocoagulation . Additionally it may be used as an adjunct before glaucoma or vitreoretinal surgery

Özet

Santral retinal ven tıkanıklığına bağlı neovasküler glokomlu olguda intravitreal bevacizumab ‘ın rubeozis iridise etkisini değerlendirmek amacıyla uygulandı. Kırkaltı yaşında erkek hastanın sağ gözünde santral retinal ven tıkanıklığına bağlı iris neovaskülarizasyonu mevcuttu ve göz içi basıncı 46 mmHg idi. Retina fotokoagülasyonuna , yüksek göz içi basıncına bağlı kornea ödemi nedeniyle devam edilememişti. İntravitreal injeksiyon öncesi ve sonrası iris anjiografisi ile morfolojik değişiklikler ve vasküler sızıntı değerlendirildi. Enjeksiyondan 2. gün -1 hafta sonra sızıntıda azalma tespit edildi.1-4 hafta arası takiplerde enflamasyon yada yeniden damarlanma izlenmedi. İntravitreal bevacizumab enjeksiyonu neovasküler glokomlu hastalarda retina fotokoagülasyonunu önleyen yetersiz görüntülümede alternatif bir tedavi olabilir. Ayrıca glokom ve vitreoretinal cerrahi öncesinde ek bir tedavi olabilir.

🔖

Cite This Article

BATIOĞLU, F., ASTAM, N., ÖZMERT, E. (2007). Intravitreal bevacizumab in a patient with neovascular glaucoma due to central retinal vein occlusion. Retina-Vitreus, Cilt: 15 - Sayı: 3, 221–223. https://ajindex.com/articles/307770

References (9)

  1. Ferrara N.: Vascular endothelial growth factor: basic science in clinical progress. Endocrinol Rev. 2004;25:581-611
  2. Kabbinavar E, Hurwitz HI, Fehrenbacher L, et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65
  3. Michels S, Rosenfeld PJ, Puliafito CA, et al.: Systemic bevacizumab (Avastin) for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label therapy. Ophthalmology. 2005;36:270-271
  4. Rosenfeld PJ, Moshfeghi AA, Puliafito CA.: Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335
  5. Rosenfeld PJ, Fung AE, Puliafito CA.: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers and Imaging. 2005;36:336-339
  6. Avery RL.: Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment. Retina. 2006;26:352-354
  7. Kahook MY, Schuman JS, Noecker RJ.: Intravitreal Bevacizumab in a patient with Neovascular Glaucoma. Ophthalmic Surg Laser Imaging. 2006;37:144-146
  8. Fernandez-Vigo J, Castro J, Macarro A.: Diabetic iris neovascularization. Natural history and treatment. Acta Ophthalmol Scand. 1997;75:89-93
  9. Adamis PA, Shima DT.: The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111-118.